{"id":"W2055340037","doi":"10.1158/1078-0432.ccr-14-1770","title":"Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Cyclophosphamide; Oncolytic virus; Medicine; Peripheral blood mononuclear cell; Neutralizing antibody; Titer; Antibody; Immunology; Immune system; Virology; Pharmacology; Chemotherapy; Internal medicine; Biology; In vitro","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007768845,0.0002099653,0.0005803494,0.0001670819,0.0002098561,0.00004984403,0.0009246298,0.0002916622,0.00009839305],"category_scores_gemma":[0.003024747,0.0002019809,0.0003221314,0.0003464438,0.0004206964,0.0000111455,0.000364964,0.0004898656,0.00003597059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009786481,"about_ca_system_score_gemma":0.001275851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003285668,"about_ca_topic_score_gemma":0.0002568779,"domain_scores_codex":[0.9955979,0.0009351613,0.0009772055,0.0008779069,0.0007494829,0.000862359],"domain_scores_gemma":[0.9966616,0.0005255889,0.0001515682,0.001165797,0.000894526,0.0006009103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.35444,0.00141237,0.00005800612,0.00005475237,0.0001252462,0.000004172751,0.0000462049,0.0007541226,0.5371103,0.00003734775,0.00110128,0.1048563],"study_design_scores_gemma":[0.06387059,0.1079468,0.00007307414,0.00007916148,0.00002251288,0.000001528655,0.00007394705,0.00208768,0.8094817,0.0003898717,0.0156235,0.0003496297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957691,0.0006778463,0.0004785184,0.000421347,0.0003225783,0.001942142,0.00006604809,0.00001535432,0.0003070357],"genre_scores_gemma":[0.994832,0.0007194874,0.0009373482,0.0003910816,0.001609529,0.0007111054,0.00005744896,0.0000809405,0.0006610894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2905694,"threshold_uncertainty_score":0.8236542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1336147238726371,"score_gpt":0.5301574505187308,"score_spread":0.3965427266460937,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}